The Role of Private Equity in Life Sciences: A Roundtable
The Role of Private Equity in Life Sciences: A Roundtable
复制标题
DOI：
10.1111/j.1745-6622.2010.00271.x
复制
发表时间：
2010-07
期刊：
影响因子：
--
通讯作者：
J. Greene;D. Purcell;B. Edelman;D. Giordano;Richard S. Ruback
中科院分区：
文献类型：
--
作者：
J. Greene;D. Purcell;B. Edelman;D. Giordano;Richard S. Ruback
在一年前发表在《华尔街日报》上的一次圆桌会议上，人们达成了一个明确的共识，即大型制药公司的研发职能效率低下，需要进行重大重组，可能是通过增加风险资本和私募股权公司的投资。在这次讨论中，一个有成就的行业从业者小组首先研究了风险投资和私募股权在早期和中期药物开发融资中发挥有意义作用的前景。在这样做的时候，他们探讨了以下问题：版权所有（c）2010摩根士丹利。
In a roundtable published in this journal a year ago, there was a clear consensus that the R&D function in big pharma was inefficient and in need of major restructuring, possibly through increased investments by venture capital and private equity firms. In this discussion, an accomplished group of industry practitioners begins by looking at the prospects for both venture capital and private equity to play meaningful roles in financing early- and mid-stage drug development. In so doing, they explore questions like the following: Copyright Copyright (c) 2010 Morgan Stanley.